Axsome Therapeutics to Present at Oppenheimer Healthcare Conference
Event summary
- Axsome Therapeutics will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 2:00 p.m. ET.
- The presentation will be available via live webcast on the company's investor relations page.
- Axsome focuses on CNS disorders, with FDA-approved treatments for major depressive disorder, narcolepsy, obstructive sleep apnea, and migraine.
- The company has multiple early and late-stage development programs addressing serious neurological and psychiatric conditions.
The big picture
Axsome Therapeutics is positioning itself as a leader in the treatment of CNS disorders, with a portfolio of FDA-approved products and a robust pipeline. The company's presentation at the Oppenheimer conference underscores its strategic focus on addressing critical gaps in care for neurological and psychiatric conditions. The success of its commercial products and the advancement of its clinical programs will be key drivers of its growth and market valuation.
What we're watching
- Commercial Success
- How the commercial performance of SUNOSI, AUVELITY, and SYMBRAVO will impact Axsome's revenue and market position.
- Regulatory Approvals
- The timing and success of obtaining additional FDA approvals for current and future product candidates.
- Clinical Development
- The pace and outcomes of ongoing and anticipated clinical trials for Axsome's product pipeline.
Related topics